Invendo Medical scores $28 mln

Invendo Medical said Thursday that it has raised $28 million in financing. Xeraya Capital led the round with participation from other investors that included TVM Capital, Wellington Partners and 360° Capital. Based in New York and Kissing, Germany, Invendo Medical is a colonoscopy system maker.

Glo AB completes $30 mln Series D

Glo has completed a $30 million Series D financing. Glo provides high-quality light source solutions for displays, illumination, and automotive sectors. A new investor led the round, with participation from existing shareholders including Wellington Partners, Teknoinvest, Nano Future Invest, Energy Future Invest, Foundation Asset Management and others.

Daniel Waterhouse joins Balderton Capital

Balderton Capital has appointed Daniel Waterhouse, formerly at Wellington Partners, as a general partner. Waterhouse will be based in London and will help lead early stage investments in the software and internet sectors.

immatics biotechnologies closes Series D

immatics biotechnologies has closed a Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer.

Middle Peak Raises $8.5M From Wellington, Seventure, Grunderfonds

Middle Peak Medical said it raised $8.5 million in a Series A financing in a deal co-led by Wellington Partners and Seventure Partners, along with seed investor High-Tech Gründerfonds Management GmbH. The money will fund development of Middle Peak’s technology for treating mitral valve disease

Gentical Raises $23.7M From Wellington, EdRIP, InnoBio, Others

Wellington Partners said it is the lead investor in a $23.7 million Series C financing round for Genticel which was closed this week. Wellington Partners committed about $5 million and the remaining came from existing shareholders, including EdRIP, IDInvest, InnoBio, IRDI and Amundi. The funds will be used primarily to finance a phase II program for the Toulouse, France-based HPV- vaccine developer’s lead product ProCervix.

Genticel Inks Over $20m Led by Wellington

Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), has raised 18.2 million euros ($23.7 million) in additional capital. Wellington Partners led the round which included all current institutional investors IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund*, IRDI and Amundi Private Equity Funds.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups